Article
Open Access
Volume 2 · Issue 3 · 2022
pp. 142–145
Hepatitis B Virus Reactivation in a Case With Non Hodgkin Lymphoma Treated by Rituximab Containing Regimen: Treatment With Dual Anti-Viral Combination
Reyhan Sevil Soysal1, Semra Paydas2
1
Department of Internal Medicine, Cukurova University Faculty of Medicine, Adana, Türkiye
2
Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Türkiye
Abstract
Rituximab is a chimeric monoclonal antibody targeting CD20 expressed on pre-B and mature B lymphocytes. This antibody has been used for a more than 20 years in cases with B cell non-Hodgkin lymphomas (B-NHL). The use of rituximab has some complications and one of the most important complications is Hepatitis B reactivation (HBV-R). HBV-R can lead to severe complications like hepatitis reactivation and death. Here we present a case with B-NHL developing HBV reactivation and successful treatment with combined anti-viral treatment.
Keywords: Hbv reactivation, rituximab, non-Hodgkin lymphoma
